Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
- Discontinue Re-pricing Following Market Expansion: Mr Umeda of PhRMA
September 19, 2011
- NIBIO Project Making Progress in Discovery of Safety Biomarkers for Evaluating Drug Toxicity
September 19, 2011
- Keizai Doyukai’s Hasegawa Has Not Given Up on 5% Corporate Tax Cut
September 14, 2011
- FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
- Mr Hasegawa of Keizai Doyukai Welcomes Incoming Noda Administration
September 12, 2011
- Sales of Class 1 OTC Drugs Recovering Since January 2010: JSMI
September 12, 2011
- JGA to Prepare Transparency GLs
September 6, 2011
- Gaining Piece of the Pie in Growing Market “Best for Fast Results”: Keizai Doyukai’s Hasegawa
September 6, 2011
- 1st Meeting of Asia Cooperation Conference to Be Held Next March
September 5, 2011
- Keeping Premium for New Drug Development Will Stimulate Drug Development, R&D Spending: PhRMA
September 5, 2011
- Industry Objects to Proposals that Would Expand Range of Drugs Subject to Re-pricing
September 5, 2011
- FPMAJ Proposes Setting NHI Prices for All Generics at or Above Minimum Statutory Prices
September 5, 2011
- JSGM Calls for Consideration of Generic Makers’ Cost Burden for Applications Based on Data in Public Domain
September 5, 2011
- Legal Prescription Rate Hits Record High 63.1% in FY2010: JPA
September 5, 2011
- JPMA Publishes Guideline for Creating eCTDs(4th Ed.)
September 1, 2011
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…